Kornimate/medical-research-clean huggingface dataset:
managing temporomandibular disorder (tmd) symptoms

Conditions: Temporomandibular Joint Disorders

Summary: the purpose of this study is to determine whether treatments targeted to the hormonal factors and the cyclicity of tmd symptoms associated with the menstrual cycle are more effective in relieving tmd pain and symptoms than standard self management treatment.

temporomandibular disorders (tmd) are a group of painful conditions involving the muscles of mastication and the temporomandibular joint. these pain problems are about twice as common in women as in men in the community, and prevalence peaks during the reproductive years. the etiology of tmd pain is unknown, but psychological stress, depression and the presence of other somatic complaints have been shown to influence the course of these disorders. prior research suggests that female reproductive hormones may also influence tmd pain. specifically, normally cycling women with tmd experience rising levels of tmd pain pre-menstrually during a time of precipitous drop in estrogen and show peak tmd pain during menses. interestingly, a secondary peak of tmd pain occurs at about the time of ovulation, another phase corresponding to rapid estrogen change. these data demonstrate a systematic relationship between levels of tmd pain and phases of the menstrual cycle. the proposed clinical trial will manipulate the behavioral and hormonal factors that are hypothesized to influence tmd pain, comparing the effects of: * a continuous oral contraceptive intervention designed to suppress menses and stabilize the hormonal environment; * a self-management intervention focused on and timed to the chronobiology of tmd symptoms across the menstrual cycle; and * a usual self-management intervention not timed to biological events. the aims of this clinical trial are to shed light on the mechanisms underlying the cyclic nature of tmd pain and symptoms in women, as well as to determine which treatment modality results in the greatest improvement in tmd pain and symptoms.

Eligibility criteria:
inclusion criteria: * tmd pain diagnosis as determined by enrollment exam at the university of washington * menstruate on a regular basis * not planning to become pregnant during the next 6 months exclusion criteria: * drug or alcohol abuse * current smoker and 35 years of age at any time during the study * live further than 1 hour driving distance from the university of washington, seattle campus * psychiatric disability

Keywords: temporomandibular disorders tmj disorders
pillcam sb3 capsule- feasibility study

Conditions: Small/Large Bowel

Summary: study hypothesis: pillcam sb3 is a new capsule designed to provide an improved image quality, and improved sb and duodenum tissue coverage due to adaptive frame rate (afr) of 2-6 fps, which will create more images for evaluation, and therefore should improve diagnostic accuracy. proposed design: to enroll up to 230 patients with symptoms suggesting the presence of small bowel disease. preparation for procedure will include 12 hours fasting prior to the capsule ingestion patients will undergo a standard capsule endoscopy. patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion. diagnostic yield of the sb3 will be calculated the physician's subjective assessment of capsule performance will be captured

* purpose of study- to assess the performance of pillcam sb3 capsule in detecting small bowel lesions in patients * study design- feasibility study * number of subjects- up to 200 * subject population- patients with symptoms suggestive of small bowel disease and whom are eligible and indicated for sb capsule endoscopy * no of centers- 4 * duration of enrollment up to 12 months from irb approval to enroll study patients * duration of follow-up 1 week after capsule procedure. * primary objectives to evaluate the performance of sb-3 system in patients as per physician questionnaire

Eligibility criteria:
inclusion criteria: 1. patient age is ≥ 18 years old, 2. patients with history suggestive and /or symptoms suggestive of small bowel disease and whom are eligible and indicated for sb capsule endoscopy, 3. patient and/or legal guardian is able and agrees to sign the informed consent form exclusion criteria 1. patient has dysphagia, 2. patient is known or is suspected to suffer from intestinal obstruction, 3. patient has known previous stricture/obstruction of the sb or colon, 4. patient has a cardiac pacemakers or other implanted electro medical devices, 5. women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception, 6. patient is expected to undergo mri examination within 7 days after ingestion of the capsule, 7. patient has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator, 8. patient has any condition, which precludes compliance with study and/or device instructions, 9. patient suffers from life threatening conditions, 10. patient is currently participating in another clinical study, 11. patient has known slow gastric emptying time

Keywords: small bowel disease
assessment of the efficacy of tracheal oxygen administration during bronchoscopy - a phase ii trial

Conditions: Hypoxaemia

Summary: the aim of the present study is to measure the time to correction of o2 saturation when in case of desaturation below 90%, o2 administration is switched from the nasal to the tracheal route at a similar flow rate.

the development of a flexible bronchoscope with a channel dedicated to o2 administration might allow optimization of the oxygen supplementation during bronchoscopy, which reduces the risk of per- and peri-procedural hypoxemia. the investigators will conduct a pilot study corroborating the hypothesis that tracheal supplementation of oxygen during flexible bronchoscopy is advantageous in comparison to nasal cannula supplementation. the concept of our trial consists of a mono-centric observational study performed in the endoscopy suite of the respiratory division, university hospitals leuven. all patients will be given informed consent before inclusion. the aim of the present study is to measure the time to correction of o2 saturation when in case of desaturation below 90%, o2 administration is switched from the nasal to the tracheal route at a similar flow rate.

Eligibility criteria:
inclusion criteria: * patients referred for flexible bronchoscopy exclusion criteria: * broncho-alveolar lavage * endobronchial plugging
reactive doses and times during oral food challenge to peanut

Conditions: Peanut Allergy

Summary: peanut allergy is a growing public health problem in developed countries with more and more hospitalizations for anaphylaxis. it has been determined that sensitization to certain peanut proteins such as rara h 2, is predictive of allergy and could predict the severity of reaction (anaphylaxis) during oral food challenges (ofc). so far, consensual threshold for cutaneous test and ige as predictor in the positivity of ofc have not been determined. identification of reactive doses for ofc and phenotype of patients would help to personalize management of patients subgroups, with an optimal security.


Eligibility criteria:
inclusion criteria: * patients with a clinical suspicion of peanut allergy who underwent ofc to peanut * patients not objecting to participate in the study * men and women are included exclusion criteria: • the patient refused to participate in the study

Keywords: anaphylaxis oral food challenge hypersensitivity food allergy peanut
accelerated prep access for black msm and tw

Conditions: HIV/AIDS

Summary: the investigators will pilot-test an accelerated prep initiation approach among young high-risk black/african american (b/aa) men who have sex with men (msm) and transgender women (ymsm/tw) at the point of care in community contexts.

the study team will provide a free 30-day supply of hiv pre-exposure prophylaxis (prep) to young black msm and tw identified as prep-eligible and interested in taking prep to reduce their risk of hiv acquisition. this intervention is intended to assist youth at high risk for hiv acquisition in successfully initiating prep use.

Eligibility criteria:
inclusion criteria: 1. ages 18-24; 2. assigned male at birth, identify as a man (cisgender), transgender woman, or gender non-conforming or genderqueer; 3. identifying as black, african american, or multiracial with at least one parent identifying as black or african american; 4. not currently taking prep or attending a visit to initiate prep; 5. self-report being hiv-negative; 6. reporting one of the following hiv risks in the last 6 months (hosek, rudy et al. 2015, hosek, rudy et al. 2017): a. condomless anal intercourse with an hiv-infected male partner or a male partner of unknown hiv status; b. anal intercourse with 3 or more male sex partners; c. exchange of money, gifts, shelter, or drugs for anal sex with a male partner; d. sex with a male partner and has had a sexually transmitted infection; e. sexual partner of an hiv-infected male with whom condoms were not consistently used; f. anal intercourse where the condom broke or slipped off exclusion criteria: * we are excluding those individuals who were assigned female at birth (female birth certificate) and/or cis-gender women (those assigned female at birth and identify as women) from the all phases of this study as this study is intended to explore the hiv prevention behaviors of b/aa young men who have sex with men and young transgender women (assigned male at birth) as these two groups represent the highest risk groups for hiv infection in the us, yet only a small percentage are aware or currently use prep for hiv prevention.

Keywords: prep hiv prevention young men who have sex with men young transgender women
a study evaluating ipi-926 in combination with gemcitabine in patients with metastatic pancreatic cancer

Conditions: Metastatic Pancreatic Cancer

Summary: study ipi-926-03 is a phase 1b/2 clinical trial to evaluate ipi 926 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. phase 1b is designed as a dose escalation study. once the maximum tolerated dose of ipi-926 in combination with gemcitabine is established in the phase 1b portion of the study, the phase 2 portion will commence. phase 2 is designed as a randomized, double-blind (investigator/patient), placebo-controlled study. there is no cross-over option for patients in either arm of the phase 2 (i.e., there is no option for patients receiving placebo to cross-over to ipi-926).

ipi 926 is an inhibitor of the hedgehog pathway. ipi-926 in combination with gemcitabine may improve therapeutic outcomes in patients with pancreatic cancer. infinity is conducting a phase 1b/2 clinical trial to evaluate the safety and efficacy of ipi-926 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Eligibility criteria:
inclusion criteria: * 18 years of age * pathologically confirmed metastatic pancreatic adenocarcinoma * at least 1 radiologically evaluable metastatic lesion (recist 1.1). * ecog 0 or 1 * life expectancy ≥3 months. * all women of child bearing potential, all sexually active male patients, and partners of patients must agree to use adequate methods of birth control * ability to adhere to the study visit schedule * voluntarily signed an informed consent form exclusion criteria: * islet cell, acinar cell carcinoma, non-adenocarcinoma, (i.e., lymphoma, sarcoma), adenocarcinoma originated from biliary tree or cystadenocarcinoma * prior treatment with chemotherapy for pancreatic cancer. * known central nervous system metastases * inadequate hematologic function * inadequate hepatic function * inadequate renal function * external (percutaneous) biliary drain * history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months. * venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation not appropriately anticoagulated or have nci ctcae grade 2 or greater bleeding episode in the 3 weeks prior to administration of ipi-926 * concurrent administration of the medications or foods known to inhibit cyp3a activity to a clinically relevant degree * presence of active infection or systemic use of antibiotics within 72 hours of treatment * significant co-morbid condition or disease which in the judgment of the investigator would place the patient at undue risk or interfere with the study. * known human immunodeficiency virus (hiv) positivity * known hypersensitivity to gemcitabine, ipi-926, or their excipients * pregnant or lactating women
how spinopelvic movements affect hip function after total hip arthroplasty

Conditions: Total Hip Replacement; Hip Dislocation; Hip Osteoarthritis

Summary: our study aims to evaluate the effect of spinopelvic movement on hip functions in individuals who have undergone total hip arthroplasty (tha). this study will contribute to the literature by helping identify and prevent issues experienced by tha patients, ranging from hip pain to limited mobility and even hip dislocation.

total hip arthroplasty (tha) is a widely accepted surgical procedure that effectively alleviates pain, enhances mobility, and improves physical function in patients with hip osteoarthritis. however, improper placement of implants during surgery can lead to complications such as abnormal edge loading, early wear of polyethylene components, ceramic insert fractures, or hip dislocations, often requiring early revision surgeries. while lewinnek's "safe zone" (30°-50° inclination and 5°-25° anteversion for the acetabular component) has traditionally been used as a guideline, recent studies have reported significant dislocation rates even within these parameters, highlighting spinopelvic movement abnormalities as a critical factor. normal spinopelvic-hip mechanics allow for adaptive changes in the pelvis and acetabulum during positional transitions, thereby preventing anterior or posterior impingement in the hip joint. however, patients with restricted lumbosacral mobility are at a greater risk of impingement-related symptoms. to address these challenges, advanced metrics such as sacral slope difference (δss), pelvic-femoral angle (pfa), and combined sagittal index (csi) have been introduced to better define functional safe zones and assess risks of hip impingement and dislocation. while the relationship between csi and hip dislocations is established, its impact on hip function remains unclear. this study aims to evaluate the effect of spinopelvic movement on hip function in individuals who have undergone tha. by identifying and preventing complications such as hip pain, mobility restrictions, and dislocations, the research seeks to provide meaningful contributions to the literature and improve patient outcomes.

Eligibility criteria:
inclusion criteria: * patients aged 60 and older. * at least 12 months post-surgery. exclusion criteria: * patients with modular neck implants, metal-metal, or ceramic bearing surfaces. * patients with hip infection or advanced osteoarthritis in the contralateral hip. * patients with leg length discrepancy. * patients with neurological, orthopedic, or systemic diseases affecting gait or balance. * patients with a body mass index (bmi) greater than 40 kg/m².
characterization by clinimetric indicators of chronic low back pain subjects versus healed patients

Conditions: Chronic Low Back Pain; Postural Low Back Pain

Summary: pretending with the use of accelerometers and pressure platform, determine indicators that are useful to therapists to assess postural control and balance, to subsequently allow to evaluate the effect of therapeutic interventions through therapeutic exercise of motor control in patients with chronic low back pain .

the records are made simultaneously with the different evaluation equipment, accelerometer and pressure platform. the tests are performed in a control group of healthy subjects, and in an experimental group with dlc receiving a program of therapeutic exercise based and pain education based on neuroscience. after the collection of the records, the behavior patterns in both groups are evaluated, the possible differences among them are established for the clinimetric indicators analyzed related to the postural control, as well as a characteristic of the sample. subsequently, through the evaluation after the intervention of the experimental group we will analyze the effect of a physiotherapy treatment based on the therapeutic exercise of motor control on parameters related to postural control and clinical variables (perceived pain, mechanosensitivity, disability and proprioceptive repositioning of the lumbar spine )

Eligibility criteria:
inclusion criteria: * low back pain with painful perception on a daily or almost daily basis for more than three months of clinical course, with or without pain radiating to the lower extremities above the knee. * not having metal implants in the spine * own ability to read and write * and access the study voluntarily. exclusion criteria: * vestibular disorders * without severe visual impairment * no medication intake with a potential effect on balance during the 90 days prior to data collection * physiotherapy treatment 2 weeks before the study

Keywords: postural control chronic low back pain therapeutic excercise healed patients
statin eligibility prior to myocardial infarction

Conditions: Statins; Myocardial Infarction

Summary: the study (statin eligibility prior to myocardial infarction (mi) in jordanians, statinepic) is 1. cross sectional 2. non interventional 3. one encounter per patient. no follow up. it addresses a major issue of primary prevention in jordanians especially the young population, namely the issue of lipid lowering agents before sustaining an acute mi. a recent study in usa showed that 50% of patients who sustained mi were not eligible to statins had they been evaluated before the heart attack. it is largely unknown if a larger percentage of middle eastern patients who sustain a heart attack would be eligible to receive lipid lowering agents. 4. the pi will overlook the whole process. dr ahmad tamari, the assistant to the pi will asses this whole process of data collection, management and manuscript drafting.

statins, when use as primary cardiovascular prevention strategy, have been shown to lower future acute cardiovascular events, especially myocardial infarction. however the use of statins in this context (i.e., primary prevention) is governed by guidelines that limit the use of statins to four high risk populations: (1) hose with known cardiovascular disease, (2) those with low-density lipoprotein cholesterol (ldl-c) levels 190 mg/dl or above, (3) diabetics with ldl-c levels 70-189 mg/dl, and (4) those with an estimated 10-year atherosclerotic cardiovascular disease risk score of 7.5% or more. unfortunately, some individuals are still at risk of sustaining mi despite the fact that they do not fit into one of these four high risk groups eligible for statins. stainepic will enroll consecutive patients admitted with mi who are not on statins to examine their eligibility for these medications based on the aha/acc guidelines.

Eligibility criteria:
inclusion criteria: * adults admitted with mi, age 30 to 75 * known lipid profile exclusion criteria: * on statin before enrollment
infection among patients undergoing radical cystectomy.

Conditions: Cystostomy Infection

Summary: investigators plan to perform a review of medical records a single urology department to identify patients with febrile perioperative infection who underwent radical cystectomy and urinary diversion for bladder cancer from january 2014 to july 2017. investigators plan assess a potential variables to find correlation with infections after surgery. characteristics, including age, sex, length of hospital stay, body mass index (bmi), diabetes, hypertension, estimated glomerular filtration rate (egfr), preoperative hydronephrosis, smoking status, neoadjuvant chemotherapy, pathological stage, lymph node involvement, types of urinary diversion, operative method (open/laparoscopic), operative time and receipt of a perioperative blood transfusion (pbt) will be asses as potential risk factor for perioperative infection.


Eligibility criteria:
inclusion criteria: * patients who underwent radical cystectomy and urinary diversion for bladder cancer. exclusion criteria: * documented infection at the time of radical cystectomy * concurrent organ resection such as nephrectomy, nephroureterectomy * partial cystectomy
dehydroepiandrosterone (dhea) and letrozole in treating patients with metastatic breast cancer

Conditions: Breast Cancer

Summary: rationale: androgens can cause the growth of breast cancer cells. hormone therapy using dehydroepiandrosterone (dhea) may fight breast cancer by blocking the use of androgen by the tumor cells. letrozole may stop the adrenal glands from making androgens. giving dhea together with letrozole may kill more tumor cells. purpose: this phase i trial is studying the side effects and best dose of dhea when given together with letrozole in treating patients with metastatic breast cancer.

objectives: * to determine the maximum tolerable dose, dose-limiting toxicity, and pharmacokinetics of dehydroepiandrosterone (dhea) when given together with letrozole in patients with androgen receptor-positive and estrogen receptor- and progesterone receptor-negative metastatic breast cancer. outline: patients receive oral dehydroepiandrosterone and oral letrozole once daily. physical exams and blood collections are performed every two weeks. tumor assessments are performed once every three months.

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer * metastatic disease * hormone receptor status * estrogen receptor- and progesterone receptor-negative * androgen receptor-positive patient characteristics: * ecog performance status 0-3 * postmenopausal (\> 60 years of age) * leukocyte count \> 3,000/ul * absolute neutrophil count \> 1,500/ul * platelet count \> 100,000/ul * total bilirubin normal * ast and alt \< 2.5 times upper limit of normal * creatinine normal or creatinine clearance \> 60 ml/min prior concurrent therapy: * at least 4 weeks since prior chemotherapy * at least 4 weeks since prior biologic therapy * at least 4 weeks since prior radiotherapy * at least 30 days since prior investigational agents * no concurrent dehydroepiandrosterone or androstenedione supplements * no concurrent chemotherapy or radiotherapy * no concurrent hormone therapy or immunotherapy (including trastuzumab \[herceptin®\])

Keywords: stage iv breast cancer recurrent breast cancer male breast cancer